RheumNow Live 2022 Pre-Learn Survey #1

Please complete this series of True-False questions as preparation for your sessions at RheumNow.live on March 19th and 20th. Responding to these “Pre-learn” surveys will take 10-15 minutes.

You can download the reading material each speaker has chosen for you to read prior to the meeting by clicking the link at the end of the survey. 

Methotrexate is equally optimized by using parenteral MTX or split-dose oral MTX.

Rituximab, anakinra and cyclosporin are all FDA-approved DMARDs that are infrequently used in RA.

Shared decision making (SDM) when choosing therapy has been proven to augment DMARD responses.

Surveys show that most RA patients are unwilling to change DMARD therapy despite having disease activity.

RF and CCP seropositivity associates with better responses to TNF inhibitors and IL-6 inhibitors.

Multiomic analysis, with machine learning, is being used to integrate genetic, epigenetic, and clinical data to identify potential biomarkers for predicting TNFi responses.

ANA positive and ANA negative SLE patients respond differently in clinical trials.

ANA negative lupus is still quite rare.

Lupus podocytopathy is a new form of lupus nephritis; a nonimmune complex-mediated nephropathy that is severe and difficult to treat.

Lupus nephritis outcomes are not predicted by changes in proteinuria.

The SEAM-PsA trial proved that methotrexate works better than etanercept in active PsA.

Risk factors for MTX hepatotoxicity include diabetes, hyperlipidemia, obesity and high alcohol consumption.

The US FDA has approved the following DMARDs for the treatment of active Psoriasis – tofacitinib, hydroxyurea and tacrolimus.

The presence of comorbidities in psoriatic arthritis is is associated with more severe disease and poorer drug responses.

×